Nuclear Imaging Agents Market to Reach USD 11.8 Billion by 2034, Growing at 7.1% CAGR Amid Rising Adoption of Precision Diagnostics and Personalized Medicine

Subheadline:
Rising cancer and cardiac-disease prevalence, advances in PET/SPECT tracers, and integration of artificial intelligence are fueling robust global growth in the nuclear imaging agents market.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72435

Introduction
The Nuclear Imaging Agents Market is undergoing rapid transformation as precision diagnostics and personalized medicine become central to modern healthcare.
Valued at USD 5.9 billion in 2024, the market is projected to reach USD 11.8 billion by 2034, registering a CAGR of 7.1% during the forecast period.

Nuclear imaging agents-radiopharmaceuticals used in positron emission tomography (PET) and single-photon emission computed tomography (SPECT)-play a vital role in detecting cancer, neurological disorders, and cardiovascular conditions. Growing demand for early disease detection, combined with innovation in isotope production and AI-enabled image analytics, is redefining diagnostic accuracy worldwide.

Key Players in the Market
The competitive landscape includes global pharmaceutical firms, isotope manufacturers, and diagnostics innovators.

Major companies include:
• GE HealthCare Technologies Inc.
• Cardinal Health Inc.
• Bracco Imaging S.p.A.
• Curium Pharma
• Lantheus Holdings Inc.
• Siemens Healthineers AG
• Jubilant Radiopharma
• Advanced Accelerator Applications (SA - a Novartis Company)
• Telix Pharmaceuticals Ltd.
• NorthStar Medical Radioisotopes LLC

These firms focus on novel PET tracers, theranostic agents, and AI-integrated imaging systems while expanding cyclotron and generator production capacity to meet global demand.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/72435/nuclear-imaging-agents-market

Key Events in the Last Five Years
• 2020-2021: Strong post-pandemic rebound in oncology imaging procedures; rapid adoption of 68Ga-based PET tracers.
• 2022: Novartis/AAA launched commercial rollout of Lutathera® and continued expansion of theranostic radioligands.
• 2023: GE HealthCare introduced OmnipetTM AI platform combining molecular imaging data with machine-learning diagnostics.
• 2024: Telix Pharmaceuticals received FDA approval for TLX250-CDx-a PET imaging agent for renal-cell carcinoma detection.

Market Growth Rate
According to Exactitude Consultancy, the market is expected to grow at a 7.1% CAGR (2025-2034), driven by:
• Increasing oncology and cardiology imaging volumes worldwide.
• Rising use of theranostic pairings (diagnostic + therapeutic isotopes).
• Technological convergence of AI, PET/CT, and SPECT/CT.
• Expanding radiopharmaceutical production capacity in the U.S., Europe, and Asia.

Market Segments and Growth Analysis
The market is segmented by isotope type, application, and region.
By Isotope Type:
• Technetium-99m (Tc-99m)
• Fluorine-18 (F-18)
• Gallium-68 (Ga-68)
• Iodine-123 (I-123)
• Others (Rubidium-82, Yttrium-90, Copper-64)

By Application:
• Oncology (breast, prostate, lung, and thyroid cancers)
• Cardiology (myocardial perfusion imaging)
• Neurology (Alzheimer's and Parkinson's diagnostics)
• Endocrinology & Infectious Diseases
• Others (Research & Theranostics)

By Region:
• North America: Dominates due to robust PET/CT network and FDA-approved tracer portfolio.
• Europe: Rapid adoption of gallium-based tracers and government-funded isotope projects.
• Asia Pacific: Fastest-growing market, led by Japan, China, and India expanding cyclotron facilities.
• Latin America & MEA: Increasing nuclear-medicine centers and collaborative radiopharmacy initiatives.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72435

Key Market Drivers
1. Rise in Chronic Diseases:
The global surge in cancer and cardiac disorders heightens demand for accurate molecular imaging.
2. Emergence of Theranostics:
Dual-purpose agents enable both imaging and targeted radiotherapy, optimizing treatment outcomes.
3. AI and Automation:
Machine-learning algorithms improve image reconstruction, tracer quantification, and reporting speed.
4. Government Support and Funding:
Investments in isotope supply chains (e.g., Mo-99 production) ensure sustainable clinical availability.

Recent Developments
• 2023: Lantheus Holdings launched PYLARIFY AITM, an FDA-cleared PET/CT quantification platform for prostate-specific membrane antigen (PSMA) imaging.
• 2024: Curium Pharma expanded its PET radiopharmacy network across Europe to enhance same-day tracer delivery.
• 2024: Bracco Imaging introduced a next-generation micro-dose cardiac PET tracer with superior biodistribution.
• 2024: NorthStar Medical Radioisotopes began commercial production of non-uranium-based Mo-99, addressing supply-chain sustainability.

Expert Insight
"Molecular imaging is entering an AI-assisted era where quantitative radiomics and theranostics merge to deliver personalized, predictive care. Continuous tracer innovation will define competitive advantage through 2034,"
- Dr. Marco Santini, Professor of Nuclear Medicine, University of Milan.

Conclusion
The Nuclear Imaging Agents Market stands as a cornerstone of precision diagnostics and targeted therapy.
With accelerating advances in radiopharmaceutical chemistry, AI analytics, and hybrid imaging systems, the market is poised for strong global growth through 2034.

Strategic collaborations between isotope producers, AI developers, and healthcare providers will further expand access and efficiency in nuclear medicine worldwide.

This report is also available in the following languages : Japanese (核イメージング剤市場), Korean (핵의학 영상제 시장), Chinese (核成像剂市场), French (Marché des agents d'imagerie nucléaire), German (Markt für nuklearmedizinische Bildgebungsagentien), and Italian (Mercato degli agenti di imaging nucleare), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72435

Our More Reports:

Subarachnoid Hemorrhage Market
https://exactitudeconsultancy.com/reports/72076/subarachnoid-hemorrhage-market

Tropical Spastic Paraparesis Market
https://exactitudeconsultancy.com/reports/72081/tropical-spastic-paraparesis-market

Dravet Syndrome (DS) Market
https://exactitudeconsultancy.com/reports/72087/dravet-syndrome-ds-market

Generalized Myasthenia Gravis (gMG) Market
https://exactitudeconsultancy.com/reports/72089/generalized-myasthenia-gravis-gmg-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.